-
2 months ago | 
onlinelibrary.wiley.com | Nicolas Girerd |Université de Lorraine |Pardeep S. Jhund
Invited Editorial Withdrawal of medical therapy for heart failure after rhythm control in arrhythmia-induced cardiomyopathy—a call for caution Guideline-directed medical therapy for heart failure in arrhythmia-induced cardiomyopathy with improved left ventricular ejection fraction Luis Manuel Domínguez-Rodríguez, David Dobarro, Carla Iglesias-Otero, María G.
-
Jan 14, 2025 | 
onlinelibrary.wiley.com | Nicolas Girerd |Université de Lorraine |CHRU Nancy |Vanessa Barbet
Introduction Heart failure (HF) is a common yet critical syndrome with a growing global incidence.1 The condition is responsible for considerable societal and economic costs, both nationally and internationally, and has involved continuous therapeutic advances to improve patient survival in the last decade.2, 3 HF represents one of the leading expenditure items for health insurance in France with €3.1 billion in 2021 and an 18.0% increase between 2015 and 2021.4 Repeated hospitalizations...
-
Nov 19, 2024 | 
onlinelibrary.wiley.com | Guillaume Baudry |Université de Lorraine |Nicolas Girerd |Maja Cikes
Introduction Heart failure (HF) is common and responsible for a substantial number of hospitalizations and increased risk of death.1 Despite advancements in treatment options for HF overall, advanced HF (AdHF) still affects over 10% of patients.2 The prognosis associated with AdHF remains poor with a 1-year risk of hospitalization or death reaching 70%.3 The management of HF with reduced ejection fraction is primarily based on neurohormonal treatments, which include four therapeutic classes...
-
Oct 28, 2024 | 
onlinelibrary.wiley.com | Anna Dieden |Nicolas Girerd |Université de Lorraine |Filip Ottosson
Introduction The progression from a healthy to a failing heart involves complex molecular, cellular, and physiological adaptations to cardiac stressors.
-
Oct 24, 2024 | 
onlinelibrary.wiley.com | Nicolas Girerd |Université de Lorraine |Adriaan A. Voors |Jozine ter Maaten
Invited Editorial Exploring the role of hypertonic saline in ambulatory heart failure management: One size does not fit all?
-
Sep 5, 2024 | 
nature.com | Fang-Fei Wei |Pierpaolo Pellicori |Joao Ferreira |Arantxa González |De-Wei An |Chen Liu | +10 more
AbstractNone of the spironolactone trials in heart failure (HF) assessed the blood pressure (BP) responses to exercise, while conflicting results were reported for exercise capacity. In the HOMAGE trial, 527 patients at increased HF risk were randomized to usual treatment with or without spironolactone (25–50 mg/day). The current substudy included 113 controls and 114 patients assigned spironolactone, who all completed the incremental shuttle walk test at baseline and months 1 and 9.
-
May 15, 2024 | 
cfrjournal.com | Harriette Van Spall |Mikhail Kosiborod |Nicolas Girerd |Michael S. Kiernan
HFA 24 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined onsite by Dr Jasper Brugts (Erasmus University Medical Centre, NL) to discuss the first results from the TITRATE-HF study.
-
May 15, 2024 | 
cfrjournal.com | Harriette Van Spall |Mikhail Kosiborod |Stefan Anker |Nicolas Girerd
HFA 2024 — Late-breaker host, Dr Harriette Van Spall sat down with Dr Mikhail Kosiborod to discuss insights from the STEP-HFpEF programme. STEP HFpEF aimed to test the hypothesis that treatment with semaglutide can improve symptoms in patients with HFpEF and obesity. This discussion centers around the background of the primary results of STEP-HFpEF, specifically in terms of the patients' NTproBNP levels.
-
May 13, 2024 | 
cfrjournal.com | Muthiah Vaduganathan |Nicolas Girerd |Michael S. Kiernan |Finn Gustafsson
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the findings from a study of four large-scale placebo controlled-trials investigating the timing of cardio-kidney protection with SGLT2 inhibitors. 4 trials that sampled distinct patient populations were enrolled in the trial - the CANVAS program, the CREDENCE trial, DAPA-HF and DELIVER.
-
May 13, 2024 | 
cfrjournal.com | Nicolas Girerd
HFA 24 - We are joined onsite by Dr Michael Kiernan (Tufts University School of Medicine, US) to discuss the findings from the PROACTIVE-HF 2 Trial. PROACTIVE-HF 2 is a prospective, multicenter, open-label randomized controlled trial which aimed to assess the device safety and efficacy of the Cordella Pulmonary Artery Sensor System in a population of 75 New-York Heart Association (NYHA) class II to III heart failure patients.
